Monoclonal Antibodies and Immunotherapy in Viral Disease

Monoclonal antibodies are laboratory-produced, identical antibodies engineered to bind a single viral target, most often a surface protein the virus uses to enter cells. Administered directly, they provide immediate, passive protection — a form of immunotherapy that complements vaccines (which take weeks to act) and small-molecule antivirals.

Definition

A neutralizing monoclonal antibody is a single, defined antibody produced in vitro that binds a specific viral epitope to block infection, used therapeutically or prophylactically as a form of passive immunization that confers immediate but temporary protection.

Scope

This topic covers neutralizing monoclonal antibodies and related immunotherapy against viral infection: how they neutralize virus, how they differ from active vaccination, their use as single agents or cocktails, and limitations such as viral escape and antibody-dependent enhancement. It is an educational overview of mechanism and evidence, not treatment guidance.

Core questions

• How do monoclonal antibodies neutralize a virus?
• How does passive antibody therapy differ from active vaccination?
• Why are antibodies sometimes combined into cocktails?
• How does viral escape limit monoclonal-antibody therapy?
• What is antibody-dependent enhancement and why does it matter?

Key concepts

• Neutralizing antibodies
• Passive versus active immunization
• Monoclonal antibody cocktails
• Epitope targeting and viral surface proteins
• Escape mutations against antibodies
• Antibody-dependent enhancement
• Prophylactic versus therapeutic use

Mechanisms

A monoclonal antibody binds a defined epitope — typically on the viral protein that mediates host-cell attachment or fusion — and blocks that step, neutralizing the virus; it can also flag infected cells for immune clearance. Because the antibody is supplied ready-made, protection is immediate but wanes as the antibody is cleared, distinguishing this passive approach from the durable active immunity vaccines build (Pollard & Bijker, 2020). Trials of the REGN-COV2 cocktail in outpatients (Weinreich et al., 2021) and of a single monoclonal in hospitalized patients (ACTIV-3/TICO, 2021) illustrate both the promise and the context-dependence of the approach. Combining antibodies that bind different epitopes into a cocktail reduces the chance that a single escape mutation defeats therapy. A theoretical hazard, antibody-dependent enhancement, in which sub-neutralizing antibody worsens rather than blocks infection, is examined for SARS-CoV-2 by Arvin et al. (2020).

Clinical relevance

Monoclonal antibodies expanded the antiviral toolkit by offering rapid passive protection for prophylaxis or early treatment, particularly for those who respond poorly to vaccines; their effect, however, depends on timing and on the circulating viral variant. This entry explains how they work and what the evidence shows, and does not constitute guidance on their use in any individual.

History

Passive antibody therapy dates to serum therapy in the early twentieth century, but the hybridoma technique made defined monoclonal antibodies possible and engineering later humanized them. The COVID-19 pandemic prompted rapid development and randomized testing of neutralizing monoclonals and cocktails (Weinreich et al., 2021; ACTIV-3/TICO, 2021), which also exposed their vulnerability to viral escape as variants emerged.

Debates

How durable is monoclonal-antibody therapy against an evolving virus?

Single antibodies are readily defeated by escape mutations, and even cocktails can lose activity as variants spread, raising the question of how to sustain effectiveness against a rapidly evolving target.

Key figures

• Ann Arvin
• Andrew Pollard

Seminal works

• weinreich-2021
• arvin-2020

Frequently asked questions

How is a monoclonal antibody different from a vaccine?

A vaccine trains the body to make its own antibodies over weeks, giving lasting protection, whereas a monoclonal antibody is given directly and protects immediately but only temporarily until it is cleared from the body.

Why are monoclonal antibodies sometimes given as a cocktail?

Combining antibodies that bind different parts of the virus makes it much harder for a single mutation to let the virus escape all of them at once, reducing the risk of resistance.